Transcript Roche Template - MONEY CONFERENCES

Ethical, Social, and Good Clinical Practice
(GCP) Aspects Of Drug Development In
Children And In Paediatric Clinical Trials
Klaus Rose,
klausrose Consulting
Pediatric Drug Development & More
[email protected]
Labels A Century Ago
918.
Source: www.wellcomecollection.org
2
Modern Drugs: Therapeutic Potential & Dangers
• 1937 a liquid anibiotic was introduced
• Solvent: Ethylen Glycole; highly toxic; no
toxicity testing. > 100 deaths, 1/3 children
• Led to revision of FDA legislation
• Next catastrophe: Thalidomide1962
• Ten cases in the USA by ‘clinical studies’
• Led to the Kefauver-Harris amendments
• Was the birth of modern labels
US Legislation Triggered Modern Drug Labels
• Date back to US legislation 1962: enforced proof of efficacy.
• Use in children mostly off-label since then.
• Voluntary Pediatric Exclusivity (PE): BPCA* 2007 after first
laws 1997 & 2002. Biologics excluded.
• Mandatory ped development: PREA*** 2003. All age groups.
Biologics included. Applies to same indication as in adults only.
• Re-authorized 2012 as FDASIA***
• BPCA &PREA resulted in multiple pediatric research on
patented drugs. Both seen by FDA as major success
*BPCA Best Pharmaceuticals for Children Act
**PREA Pediatric Research Equity Act
***FDASIA FDA Safety & Innovation Act
4
klausrose Consulting
EU Pediatric Regulation
• In force since January 2007
• Combines mandatory development
with reward
• Pediatric Investigation Plan (PIP) mandatory end of human PK
• Without approved PIP Marketing Authorisation Application (MAA)
is blocked
• PIP must cover all age groups
• Pediatric Committee (PDCO) assesses PIPs, waivers & deferrals
• Reward of six months SPC* prolongation
5
-7-
klausrose Consulting
EU Pediatric Regulation: Core Elements
• FDA started with looking for ‘some‘ pediatric data
• EU wants, as far as possible, full pediatric indication(s)
• Want the necessary data as soon as possible for marketed drugs
and as early as possible for new drugs
• Expect each company to be knowledgeable + up to date
• EMEA / PDCO style: has evolved since 2007. Claim to be sciencedriven, but have developed a tough attitude
• Some requests can be perceived as exaggerated. Dictate clinical
trials even if they do not make sense
6
-9-
klausrose Consulting
Regulatory & Scientific Challenge: Earlier
Inclusion of Children In Drug Developemnt
Basic Research
EU Pediatric Investigation Plan (PIP):
mandatory at end of human PK
Entry into Man
Proof of Concept (PoC)
Phase II+III
Registration 1st Country
Patent-protected Market
Patent Expiry  Generic Competition
FDA: Early dialogue recommended;
Ped Plan mandatory at submission
7
- 10 -
klausrose Consulting
8
Pediatric Homework
• Does the same indication exist in children?
• Diagnostics: which other diseases might be diagnosed?
• Drugs: which other pediatric diseases might be qualified as being
within the ‘condition’ the drug is developed in?
• PDCO view: potential future use in children. May be different from
future adult use.
• Which therapeutic alternatives exist in children?
• Risk/benefit assessment of ped development
9
klausrose Consulting
PIP Structure
Part A: Procedure for the assessment of the application
b
Part B: Overall Development Of The Drug & Target Disease
Part C: Product-Specific Waivers
Part D: Pediatric Investigation Plan
D1 Proposed ped dev: indication, age grups, existing data
D2 Quality (CMC, technical staff)
D3 Non-clinical aspects
D4 Clinical aspects: clinical strategy & individual studies
D5 Timeslines of proposesd measures
Part E Applications for Deferrals
klausrose Consulting
10
PDCO Oral Explanation: Room & Sitting
15 m
PDCO
Chairman
Applicant‘s
Speaker
PDCO Members
EMA Representatives
[email protected]
11
Applicant Representatives
Case Study Coronary Artery Disease (CAD)
• Nykomed requested a full waiver for a diagnostic agent for coronary artery disease (CAD), a disease
listed on the class waiver list
• EMA: condition is “Visualisation of myocardial perfusion for diagnostic purposes”. Myocardial perfusion
deficits exists in children (congenital heart defects, coronary anomalies, cardiomyopathies)
• Negative opinion 2008
• Applicant took EMA to EU Court of Justice; 1st instance backed EMA
• US originator company negotiated a new PIP with EMA, agreed 2011
• Danish company continued law suit . EU General Court backed EMA 2011: otherwise it would be too
easy for companies to circumvent pediatric development.
•
[email protected]
12
EMA Decisions Perflubutane
• EMA decision of 28 November 2008 on the application for product
specific waiver for perflubutane EMEA-000194-PIP01-08 in
accordance with Regulation (EC) No 1901/2006 of the European
Parliament and of the Council as amended.
http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decisi
on/WC500005753.pdf
• EMA decision of 18 May 2011 on the agreement of a paediatric
investigation plan and on the granting of a deferral and on the
granting of a waiver for perflubutane (EMEA-000194-PIP03-10)
http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decisi
on/WC500107411.pdf
13
EU Court of Justice Decisions
• Order of the President of the Court of First Instance of 24 April 2009 –
Nycomed Danmark v EMEA (Case T-52/09 R).
http://curia.europa.eu/juris/document/document.jsf?text=&docid=734
53&pageIndex=0&doclang=EN&mode=lst&dir=&occ=first&part=1&cid
=327397
• Judgment Of The General Court (Third Chamber) 14 December
2011.
http://curia.europa.eu/juris/document/document.jsf?text=&docid=1165
83&pageIndex=0&doclang=EN&mode=doc&dir=&occ=first&part=1&c
id=234507
[email protected]
14
PIP Decisions
•
•
•
•
So far > 1000 PIPs have been submitted
The key elements are published, but not the details
Details are always confidential
Nevertheless, we can see trends in specific areas
 Melanoma
- Joint injuries
- Vaccines
- Drugs for preterm newborns
- Drugs developed only for children
- Rare diseases
Melanoma
• Class waiver for melanoma was revoked
• Justification: 1.7/ 100’000 15-19ys olds in US statistics Surveillance,
Epidemiology & End Results (SEER), www.seer.cancer.gov
• 6 PIPs if you search with ‘melanoma’: Ipilimumab (2); MAGE-A3
recombinant protein; GSK1120212; GSK2118436; RO5185426
- Ipilimumab [BMS] conditions: melanoma (PIP 1) and solid
malignant tumours excluding melanoma (PIP 2)
- Mage-A3 recombinant protein: Condition: melanoma
- GSK1120212: Condition: Melanoma & malignant solid tumours
(excluding melanoma)
- GSK2118436: Condition: Melanoma & malignant solid tumours
(excluding melanoma)
- RO5185426: Condition: Melanoma
Ipilimumab (Yervoy)
• Condition: melanoma and non-melanoma solid tumors (2 PIPs)
• Studies for melanoma:
1. i.v. study of pre- and postnatal development in cynomolgus
monkeys with a 6-month postnatal evaluation.
2. OL, dose escalation clinical trial of intravenously administered
ipilimumab in children from 2 to less than 18 years (and in young
adults to 21 years) with untreatable, refractory or relapsed solid
malignant tumours.
3. OL multi-centre, single-arm i.v. ipilimumab in 12 to <18 y with
untreated/ previously treated advanced/metastatic melanoma.
4. OL randomized active-controlled study: adjuvant ipilimumab antiCTLA4 therapy vs. high-dose interferon α-2b in kids 12 - < 18 y
(and adults) with resected high-risk melanoma.
Does This Make Sense?
• Obviously, PDCO wants to do “something” for children with
melanoma. No doubt about their good intentions.
• It would be unethical to disallow adolescents or children with
melanoma participation in adults trials.
• Once an adult melanoma drug is registered in adults, of course
clinicians will use it in children as well. Too few patients for
statistically significant results
• As companies have to commit to studies to be finished in a defined
time horizon, the pediatric patients with melanoma are now blocked
for PDCO-triggered clinical trials.
• Has started to affect e.g. US children with cancer, although the
clinical community sees other priorities
• In consequence, danger of blocking promising treatments
18
klausrose Consulting
Societal Impact of EU & US Pediatric Legislation
• Increases cost of drug development
• For large companies costs are still marginal.
• Can be different for an individual small / medium company
• SME office @ EMA offers help, but PDCO treat all applicants equally
• Higher costs for pediatric medicines have not yet reached calculations
of insurers / reimbursement institutions
• Takes decision power away from originating companies
• Does not contribute to pharmaceutical innovation in Europe
• Has increased the weight of academic pediatrics
• Many clinicians still have a generally positive view
• Assessment of relation of resources assigned to resulting clinical- 19 benefit for children almost impossible due to confidentiality
19
Light at The End of The Tunnel?
• EMA report to EU Commission emphasizes need for penalties
• EMA 5 years report July 2012 to EU Commission & EU Parliament:
“Work is well advanced to promote less detailed PIP proposals,
including the key elements in PIP opinions. The simplification of
applications and subsequently of PDCO opinions should benefit early
PIP applications …”
• First changes were presented by EMA at the EFGCP/DIA/EMA
pediatric conference September 2012 in London, UK
• General revocation of class waivers in pediatric oncology was
announced a few days ago
• Revision of pediatric regulation in 2018: reasonable modification of the
regulation to be expected?
[email protected]
20
Conclusions
• Drug development no longer possible without considering children
• Increases cost & complexity of drug development
• Mosaic of goodwill, scientific input, bureaucracy without checks &
balances, disproportionate use of resources, limited clinical benefit
• PIP skills needed: intimate knowledge of PDCO, EMA & procedures
• Potential for saving resources is highest during early PIP preparation
• Aim for individual company: negotiate PIP that will serve child health in
the far future and lets company survive
• Revision 2018: divergent proposals will be made
• EU Council’s Lisbon strategy 2000: EU by 2010 “to become the most
competitive and dynamic knowledge-based economy in the world”
• EU pediatric legislation should be seen in this framework. Is one of
many EU challenges. Good intentions are not enough
• Legislation will stay  no alternative than to continue the dialogue
[email protected]
21
Thank You For
Your Attention!
- 22 22
klausrose Consulting
Back-Ups
- 23 23
klausrose Consulting
Better Medicines for Children or Better Use of
Adult Medicines in Children?
• EU & US pediatric pharmaceutical legislation tries to close a
gap - in the use of existing adult drugs in children
• So far, there is no industry that develops drugs for children
• Such an industry could exist if there would be a market
• There are enough rare diseases to keep thousands of
researchers busy – but somebody has to pay
• Today, not even a straw facilitating intake of antibiotics is
reimursed in Germany – formulation was abandoned
• We talk about two issues: (1) Handling additional pediatric
requests in adult development, and (2) nice wording: ‘better
medicines for children’
[email protected]
24
Age Groups (ICH E 11)
Preterm newborn infants
(0 - 27 days)
*ICH E 11
Term newborn infants
(0 - 27 days)
Infants and toddlers
(28 days to 23 months)
Children (2 - 11 years)
Adolescents (12 to 16-18
years): US 16 y / EU 18 y
- 25 -
klausrose Consulting
25
26
klausrose Consulting
Will be released May 2010
27
klausrose Consulting
PDCO Summary Report Template D.1.b:
” The Regulation considers the need for data in the paediatric use.
This can be based on the potential for off-label use in children. The
Regulation does not require that the PIP is limited to the
proposed wording of the adult indication, but it is assumed that
there should be some relationship”
28
klausrose Consulting
EMA/ PDCO Feedbacks & Reports
• Requests for modification for validation
• Day 30 report: no action required from applicant
• Day 60 report: lists requested modifications: must be answered
• Day 90 report: lists requested last modifications
• Day 120: Showdown AND only chance for F2F Oral Explanation (OE)
29
klausrose Consulting
Waivers
• Waivers are given for all children or specific age groups
• Age classifcation based on ICH E 11
• Waivers only for 3 conditions:
– Drug probably ineffective or unsafe
– Disease doesn‘t exist in children
– No significant therapeutic benefit
- 30 30
klausrose Consulting
Deferrals
• Allows company to perform pediatric measures (studies,
technical development etc.) at a later defined time point
• Only concrete measures can be deferred
• Basic framework outlined in ICH E 11:
– Will for most new drugs be granted as long as there are not
sufficient safety & efficacy data in adults
– Will for marketed drugs with off-label pediatric use be very
difficult to obtain
- 31 -
klausrose Consulting
31
•
Melanoma PIP Considerations
Classification as adolescent disease refers to US data 15-19ys olds.
Ovarial carcinoma, 1.4/100’000 in 15-19y: class waiver stays.
• Deducing 2/5 from 1.7 (18/ 19 y old are adults) & 2/5 of 1.4  lower
limit 1.02 - 0.84/ 100’000 as limit for ultra rare disease? Not official
• Melanom ist rare < 18; most are detected without metastases. With
these case numbers no statistically significant results possible
→ Separate clin studies in adolescent melanoma ethically questionable
• Adolescents should have the right to participate at adult studies, but
• No PIPs for more frequent pediatric cancer types – because they
don’t exist in adults & hence no business case for drug development
• Starts to negatively impact pediatric cancer research worldwide as
PDCO decisions block pediatric patients
Cartilage Disorders
• ACT (autologous chondrocyte transplantation) routine in treating
cartilage injuries. Belated registration required by German law  PIP.
• Two published chondrocyte PIPs:
 Autologous cartilage derived cultured chondrocytes (Genzyme)
 Culture expanded autologous chondrocytes (Fidia, Italy)
• Genzyme: Retrospective investigation of S and prospective
investigation of S&E data in ped patients treated for cartilage defects
with autologous cartilage derived cultured chondrocytes. Pediatric
population from closure of femoral epiphyseal growth plate to <18 y.
• Fidia: Randomized MC S&E study of Hyalograft autologous
chondrocyte implantation compared to microfracture in 16-17y olds
• An adolescent‘s knee is biologically the same as a young adult‘s one
• PDCO uses legal age to order medically & ethically questionable trials
More Examples
• Vaccines: were developed for decades without PDCO
• Drugs for preterm newborns: development team’s competence is
sufficient to develop drug from research to registration – for which
CHMP is responsible. Addition ‘input’ from PDCO not helpful.
• Drugs developed only for children: there are a few companies who
dare. Addition ‘input’ from PDCO not helpful.
• Rare diseases starting in childhood. Drug development requires very
special knowledge. MAA is discussed with CHMP. Mandatory
additional PDCO discussion perceived as waist of time & resources
by industry
Dosing In Adolescents
• In an FDA hearing 2012 12 of 13 clinicians voted for the routine
acceptance of adult doses in adolescents
• Was based on an FDA report on adolescent PK Studies
• Discussion is ongoing in the pediatric scientific press
• FDA publications and massive advances in pediatric dosing in
pharmaceutical companies
- 35 -
EU Ombudsman
• Two companies complained against EMA/PDCO @ EU ombudsman
• The EU ombudsman concluded that in contrast to EMA’s position the
complaint fell within the scope of ‘maladministration’ and hence, under
his mandate.
• The enquiry resulted in recommending, inter alia,EMA guidelines to
assist PDCO to follow a coherent structure of analysis in future cases.
• We will later today hear more directly from a representative of the EU
ombudsman’s office!
• alia, EMA guidelines to assist PDCO to follow a coherent structure of
analysis in future cases
- 36 -
Resources
• Big companies: PIP is one of many many challenges
• SMEs: limited resources. Additional PIP challenge is usually much
more time consuming than originally thought
• Estimated consulting dimensions:
• Regulatory PIP consulting: 200-300 hours
• Clinical input should come from the sponsoring company
• Deep clinical consulting can increase the effort by factor 3 to 5
• This does not include additional internal costs by the sponsor
and not the costs of PIP execution
• Even best external consulting will not allow the sponsoring company
to just forget pediatrics
37
klausrose Consulting
PIP Execution
• Ca. 20 – 30‘000 € / costs per patient  Study 100 adults ~ 2-3 Mio €
• Multiply with factor P for pediatric studies
• More patients  higher costs
• Additional costs: juvenile animal studies, pediatric formulation,
establish a registry, etc.
• BD&L rough estimate if you buy a product where pediatric homework
has not been done: ~ 20 Mio € (including study execution, provided
your MAA is not blocked
• A part of this money must be invested before MAA, a part thereafter
38
klausrose Consulting